Project Grant R01CA276938
Award Date
1/5/23
Completion Date
12/31/27
Dollars Obligated
$878K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
미국 뉴욕
Similar Awards
This five-year $360,281 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research under the Cancer Biology Research program (CFDA 93.396). The grantee, Washington University, will conduct studies to define the contribution of altered epigenetic patterns and genome organization to the pathogenesis of acute myeloid leukemia (AML). Researchers will perform comprehensive epigenetic analysis of DNA methylation and three-dimensional...
This Project Grant award, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports research aimed at developing more effective and durable therapies for acute myeloid leukemia (AML). The $387,630 award, made on July 3, 2024, will fund a study to characterize distinct leukemia-initiating cell (LIC) subtypes and their vulnerabilities in order to design improved treatment strategies. The key objectives are to: 1) Characterize the pathways and...
The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $734,435 Project Grant to the Beckman Research Institute of the City of Hope to investigate the use of AMP synthesis inhibitors to overcome resistance to BH3 mimetic drugs in the treatment of acute myeloid leukemia (AML), particularly in older patients. The grant aims to: 1) correlate ADSS2 levels with BH3 mimetic responsiveness in primary AML cells, 2) define how ADSS-dependent AMPK activity promotes resistance to...
This $487,542 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to understand the role of mitochondrial RNA modifications in acute myeloid leukemia (AML), a highly aggressive blood cancer. The research, conducted by the Beckman Research Institute of the City of Hope, aims to determine the functional importance of the mitochondrial methyltransferase METTL17 in AML pathogenesis, elucidate the molecular mechanisms by which...
This $590,960 Cooperative Agreement award from the National Cancer Institute under the Cancer Biology Research (CFDA 93.396) program supports research at the Beckman Research Institute of the City of Hope to model the dynamics of the transcriptome and leukemia potential in acute myeloid leukemia (AML). The key objectives are to: 1) quantify leukemia potential dynamics driven by different oncogenic signals in murine models, 2) evaluate the effects of treatment on the leukemia potential to...
This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.396 Cancer Biology Research), supports scientific research to investigate the fundamental biological mechanisms underlying the development and progression of acute myeloid leukemia (AML). The $487,973 award, granted to The Leland Stanford Junior University, will fund a 5-year research project focused on understanding the role of pre-leukemic hematopoietic stem cells and clonal hematopoiesis in AML...
This Project Grant award of $458,698 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at the University of Michigan to study novel genes that influence therapy resistance and relapse in acute myeloid leukemia (AML). The research aims to identify cellular and molecular mechanisms underlying the persistence and regrowth of leukemic cells after treatment, with the goal of improving AML therapy and patient outcomes. Over the 5-year project period from...
The National Cancer Institute awarded a $342,102 Project Grant (CFDA 93.398 - Cancer Research Manpower) to The Johns Hopkins University to elucidate the role of the chromatin regulator HMGA1 in KMT2A-rearranged acute myeloid leukemia (AML). The research aims to define how HMGA1 drives leukemogenesis and chemoresistance in this aggressive form of AML, and determine how HMGA1 induces the expression of key leukemogenic HOX genes and represses the CDKN1A tumor suppressor. This 2.25-year project,...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development and optimization of a scalable, cost-effective single-cell multi-omic profiling method (SHARE-ME-SEQ) that can jointly capture gene expression, chromatin accessibility, and DNA methylation. The $237,023 award, spanning March 2025 to February 2028, will enable the Icahn School of Medicine at Mount Sinai to apply this technology to analyze bone marrow samples from healthy...
The National Cancer Institute (NCI) awarded a $768,437 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Sanford Burnham Prebys Medical Discovery Institute (SBP) to implement high-throughput screening assays to identify chemical compounds that inhibit the chromatin reader SGF29. This project aims to develop novel chemical probes and potential therapeutic candidates for acute myeloid leukemia (AML), as SGF29 has been identified as a potent regulator of AML oncogene...